ArticleJournal of nanobiotechnology2026
Nootkatone confers MAOB-dependent neuroprotection against ferroptotic injury via brain-targeted nanoparticle delivery in ischemic stroke.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDespite advances in reperfusion therapy, effective neuroprotective interventions for ischemic stroke that can be reliably translated into clinical benefit are lacking. A persistent obstacle is the frequent disconnect between mechanistic validity and effective drug exposure within the injured brain, a limitation that is particularly evident for natural products with pleiotropic but weakly defined modes of action. Nootkatone (NKT), a naturally occurring sesquiterpenoid, has antioxidant and neuroprotective activity, yet its direct molecular target and translational limitations in ischemic stroke remain unresolved. This study aimed to define a target-anchored mechanism for NKT and to determine whether improving brain exposure is required to translate this mechanism into effective neuroprotection.
resultsThrough an integrative disease-informed target discovery strategy combining network-based prediction, structure-informed docking, and cross-species biochemical validation, monoamine oxidase B was identified as the primary molecular target engaged by NKT. Pharmacological inhibition or genetic suppression of monoamine oxidase B (MAOB) activated an Nrf2-dependent antioxidant program, reinforced glutathione homeostasis, suppressed lipid peroxidation and ferroptotic injury, preserved mitochondrial integrity, and conferred robust neuroprotection in neuronal oxygen-glucose deprivation models and in mice subjected to transient cerebral ischemia. NKT was encapsulated within a hyaluronic acid modified polyethylene glycol nanocarrier engineered to increase circulation stability and lesion-associated accumulation and to improve brain exposure. This nanodelivery strategy markedly strengthened the neuroprotective efficacy and functional recovery in vivo while preserving the same intracellular signaling mechanisms observed with the free compound, indicating improved pharmacological activity rather than altered bioactivity.
conclusionsThese findings establish MAOB as a druggable mitochondrial redox regulator underlying NKT-mediated neuroprotection. In parallel, the results demonstrated that insufficient brain exposure represents a critical barrier to converting this mechanism into a consistent therapeutic benefit after stroke. By resolving both target definitions and exposure limitations within a single experimental framework, this study explains a major source of inconsistency in natural product-based neuroprotection and provides a practical strategy for achieving reproducible neuroprotective efficacy in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.